atypical lobular hyperplasia


Also found in: Acronyms.

atypical lobular hyperplasia

A relatively uncommon lesion of the female breast characterised by lobules containing uniform dyshesive epithelial cells with eccentric nuclei, often accompanied by intracytoplasmic mucin vacuoles (so-called“private acini”); the surrounding myoepithelial cell layer is retained. It is a non-palpable lesion seen in 1% to 3.6% of female breasts and carries a general increase in the risk of future breast cancer.
Mentioned in ?
References in periodicals archive ?
Comparative genomic hybridization analysis of lobular carcinoma in situ and atypical lobular hyperplasia and potential roles for gains and losses of genetic material in breast neoplasia.
Current Concepts in Diagnosis, Molecular Features, and Management of Lobular Carcinoma In Situ of the Breast With a Discussion of Morphologic Variants
24 for those with atypical lobular hyperplasia, and 8.
Atypical lobular hyperplasia has higher breast Ca risk than ductal
a) Significant pathologic findings include atypical ductal hyperplasia, atypical lobular hyperplasia, lobular carcinoma in situ, ductal carcinoma in situ, and invasive carcinoma.
Recommendations for Pathologic Evaluation of Reduction Mammoplasty Specimens: A Prospective Study With Systematic Tissue Sampling
An MMP-9-positive / ADAM 12-negative urine sample conferred a 40% chance that the patient had LCIS and a 25% chance that she had atypical ductal hyperplasia or atypical lobular hyperplasia.
Urine test enhances breast ca risk picture
An MMP-9-positive/ADAM12-negative urine sample conferred a 40% chance that the patient had LCIS and a 25% chance that she had atypical ductal hyperplasia or atypical lobular hyperplasia.
Urine test promising for assessing breast cancer risk
As pathologists we need to use uniform criteria and terminology in the diagnosis of atypical ductal hyperplasia, atypical lobular hyperplasia, and FEA.
Mitigating Overdiagnosis and Overtreatment in Breast Cancer: What Is the Role of the Pathologist?
The term lobular neoplasia (LN) was introduced by Haagensen et al (1) in 1978 and encompasses the spectrum of disease including atypical lobular hyperplasia (ALH) and lobular carcinoma in situ (LCIS), the latter of which is further divided into classic and pleomorphic types.
Lobular Neoplasia: Morphology and Management
Lobular carcinoma in situ (LCIS) and atypical lobular hyperplasia (ALH) are infrequent findings in needle core biopsy samples, occurring in approximately 0.
Pathologic upgrade rates on subsequent excision when lobular carcinoma in situ is the primary diagnosis in the needle core biopsy with special attention to the radiographic target
Four cases had concurrent atypical ductal hyperplasia (ADH), and one had atypical lobular hyperplasia.
Atypical apocrine adenosis of the breast: long-term follow-up in 37 patients
Importantly, in most cases, classic lobular carcinoma in situ or atypical lobular hyperplasia is found adjacent to the PLCIS.
Clinical implications of margin involvement by pleomorphic lobular carcinoma in situ
Although other definitions exist, the threshold used in this study for the distinction of LCIS versus atypical lobular hyperplasia was involvement of at least 75% of the units of a lobule.
Lobular carcinoma in situ variants in breast cores: potential for misdiagnosis, upgrade rates at surgical excision, and practical implications
Page et al (6) reviewed follow-up data on 261 benign breast biopsies with atypical lobular hyperplasia (ALH) taken from 252 women between 1950 and 1985.
Lobular neoplasia of the breast: an update

Medical browser ?
Full browser ?